DBV Technologies S.A.

NasdaqGS:DBVT Stock Report

Market Cap: US$128.3m

DBV Technologies Management

Management criteria checks 3/4

DBV Technologies' CEO is Daniel Tassé, appointed in Nov 2018, has a tenure of 5.42 years. total yearly compensation is $2.40M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth $22.80K. The average tenure of the management team and the board of directors is 4.7 years and 5.1 years respectively.

Key information

Daniel Tassé

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage25.0%
CEO tenure5.4yrs
CEO ownership0.02%
Management average tenure4.7yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

Sep 21

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

Aug 01

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

Jul 07

DBV Technologies reports change in U.S. reporting status, cuts headcount

Jan 07

DBV Technologies CSO Hugh Sampson to step down from role

Nov 24

DBV Technologies shares rockets 85% as EMA approves Viaskin Peanut application

Nov 02

CEO Compensation Analysis

How has Daniel Tassé's remuneration changed compared to DBV Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$600k

-US$73m

Sep 30 2023n/an/a

-US$101m

Jun 30 2023n/an/a

-US$101m

Mar 31 2023n/an/a

-US$100m

Dec 31 2022US$3mUS$600k

-US$96m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$2mUS$600k

-US$98m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$131m

Mar 31 2021n/an/a

-US$148m

Dec 31 2020US$2mUS$600k

-US$160m

Sep 30 2020n/an/a

-US$161m

Jun 30 2020n/an/a

-US$171m

Mar 31 2020n/an/a

-US$169m

Dec 31 2019US$3mUS$600k

-US$172m

Sep 30 2019n/an/a

-US$176m

Jun 30 2019n/an/a

-US$198m

Mar 31 2019n/an/a

-US$191m

Dec 31 2018US$5mUS$55k

-US$190m

Compensation vs Market: Daniel's total compensation ($USD2.40M) is above average for companies of similar size in the US market ($USD670.12K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.

CEO

Daniel Tassé (63 yo)

5.4yrs

Tenure

US$2,404,486

Compensation

Mr. Daniel Tasse had been an Independent Non-Executive Director of Indivior PLC since August 2014 until May 6, 2021 and Senior Independent Director since September 30, 2016 until May 6, 2021. Mr. Tasse ser...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Tassé
CEO & Director5.4yrsUS$2.40m0.018%
$ 22.8k
Virginie Simone Jeanine Boucinha
CFO & Principal Accounting Officerless than a yearUS$509.31kno data
Pharis Mohideen
Chief Medical Officer4.8yrsUS$1.28m0.021%
$ 26.3k
Kevin Malobisky
Chief Operations Officerless than a yearno datano data
Michele Robertson
Chief Legal Officer3.2yrsno datano data
Caroline Daniere
Chief Human Resources Officer & Chief of Staff4.6yrsno datano data
Wence Agbotounou
Chief Clinical Trial Officer & Senior VP7.9yrsno datano data
Edward Jordan
Senior Vice President of Commercial Operations North America8.3yrsno datano data
Alan Kerr
Senior VP & Head of Global Regulatory Affairs5.3yrsno datano data
Pascal Wotling
Chief External Manufacturing & Supply Chain Officerless than a yearno datano data

4.7yrs

Average Tenure

55yo

Average Age

Experienced Management: DBVT's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Tassé
CEO & Director5.1yrsUS$2.40m0.018%
$ 22.8k
Timothy Morris
Independent Director3.1yrsUS$113.54k0.012%
$ 16.0k
Michel de Rosen
Independent Chairman of the Board5.9yrsUS$10.81k0.025%
$ 31.4k
Michael Goller
Director8.5yrsUS$113.54k0%
$ 0
Daniel Soland
Independent Director9.1yrsUS$113.54k0.026%
$ 33.3k
Mailys Ferrere
Director7.8yrsno datano data
Hugh Sampson
Scientific Adviser to the CEO & Chairman of Scientific Advisory Board3.3yrsno datano data
Paul-Henri Lambert
Member of the Scientific Advisory Boardno datano datano data
Emma Guttman-Yassky
Member of Scientific Advisory Board4.9yrsno datano data
Julie O'Neill
Director6.8yrsUS$113.54k0%
$ 0
Jean-François Nicolas
Member of Scientific Advisory Board4.9yrsno datano data
Jim Krueger
Member of Scientific Advisory Board4.9yrsno datano data

5.1yrs

Average Tenure

63yo

Average Age

Experienced Board: DBVT's board of directors are considered experienced (5.1 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.